SCHEMBL26089883

SCHEMBL26089883

O=C(NC1CC2(C1)CN(Cc1ccccc1)C2)N1CCN(c2ccc(C(F)(F)F)cn2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 6/20 0.64
CHRM1 P11229 4/20 0.64
SMN1; SMN2 Q16637 4/20 0.57
HTT P42858 3/20 0.57
LMNA P02545 3/20 0.57
MAPT P10636 1/20 0.57
CHRM4 P08173 4/20 0.53
KDM4E B2RXH2 4/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CHRM5 P08912 1/20 0.47
CHRM3 P20309 1/20 0.47
ADAM10 O14672 1/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
MMP7 P09237 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP12 P39900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26087044 0.89 CHRM2 (0.63) CHRM2CHRM1SMN1; SMN2HTTLMNA
SCHEMBL23744108 0.87 CHRM2 (0.76) CHRM2CHRM1SMN1; SMN2HTTLMNA
SCHEMBL26086714 0.84 CHRM2 (0.57) CHRM2CHRM1SMN1; SMN2HTTLMNA
SCHEMBL30345522 0.84 CHRM2 (0.57) CHRM2CHRM1SMN1; SMN2HTTLMNA
SCHEMBL26090321 0.80 CHRM2 (0.49) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL26089404 0.78 CHRM1 (0.66) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL26089717 0.78 CHRM1 (0.66) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL29432226 0.78 CHRM2 (1.00) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL26133242 0.77 CHRM4 (0.63) CHRM2CHRM1CHRM4CHRM5CHRM3
SCHEMBL24945791 0.77 CHRM2 (0.45) CHRM2CHRM1CHRM4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP claimed
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 CHRM2 2/4885CHRM1 5/4885SMN1; SMN2 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.